Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care

Revista Espanola de Enfermedades Digestivas

Volumn 107, Issue 11, 2015, Pages 652-658

  Villamañán, Elena ^a   Ruano, Margarita ^a   Lara, Catalina ^a   Suárez de Parga, José Manuel ^a   Armada, Eduardo ^a   Álvarez Sala, Rodolfo ^a   Pérez, Ester ^a   Herrero, Alicia ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Hospitals; Overutilization; Proton pump inhibitor

Indexed keywords

ESOMEPRAZOLE; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AMBULATORY CARE; ARTICLE; CROSS-SECTIONAL STUDY; DUODENUM ULCER; FEMALE; GASTROESOPHAGEAL REFLUX; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT; POLYPHARMACY; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK FACTOR; STOMACH HEMORRHAGE; STRESS ULCER; ZOLLINGER ELLISON SYNDROME; AGED; EPIDEMIOLOGY; HOSPITALIZATION; INAPPROPRIATE PRESCRIBING; MIDDLE AGED; PHARMACIST; PREVALENCE; PRIMARY HEALTH CARE; SPAIN; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; FEMALE; HOSPITALIZATION; HUMANS; INAPPROPRIATE PRESCRIBING; INPATIENTS; MALE; MIDDLE AGED; OUTPATIENTS; PHARMACISTS; PREVALENCE; PRIMARY HEALTH CARE; PROTON PUMP INHIBITORS; SPAIN;

EID: 84951036570     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Sánchez Cuén JA, Irineo Cabrales AB, Bernal-Magaña G, et al. Indicaciones inadecuadas en el consumo crónico de inhibidores de bomba de protones en un hospital de México. Estudio transversal. Rev Esp Enferm Dig 2013; 105: 131-7.
2. Ponce J, Vegazo O, Beltrán B, et al. Prevalence and factors associated with gastro-oesophageal reflux disease (GORD) in Spain. Aliment Pharmacol Ther 2006; 23: 175-84. DOI: 10.1111/j.1365-2036.2006.02733. x
3. Ponce J, Esplugues JV. Racionalizar el uso de IBP: una asignatura pendiente. Rev Esp Enferm Dig 2013; 105: 21-4. DOI: 10.4321/S1130-01082013000300001
4. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317: 452-6. DOI: 10.1136/bmj.317.7156.452
5. García del Pozo J. Estudio de utilización de antiulcerosos en España (2000-2008). IT del Sistema Nacional de Salud 2009; 33(2).
6. Thomson A, Sauve M, Kassam N, et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16: 2323-30. DOI: 10.3748/wjg. v16. i19.2323
7. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-53. DOI: 10.1001/jama.296.24.2947
8. Eom CS, Park SM, Myung SK, et al. Use of acid-suppressive drugs and risk of fracture: A meta-analysis of observational studies. Ann Fam Med 2011; 9: 257-67. DOI: 10.1370/afm.1243
9. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. Eur J Intern Med 2011; 22: 205-10. DOI: 10.1016/j. ejim.2010.11.009
10. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: A national population study. Br J Clin Pharmacol 2010; 69: 543-52. DOI: 10.1111/j.1365-2125.2010.03628. x.
11. Hanzat H, Sun H, Ford JC, et al. Inappropriate prescribing of proton pump inhibitors in older patients. Effects on an educational strategy. Drugs Aging 2012; 29: 681-90. DOI: 10.2165/11632700-000000000-00000
12. Product Characteristics. Spanish Agency of Medicines and Medical Devices. Available at: http://www. aemps. gob. es/cima/fichasTecnicas. do?metodo=detalleForm (accessed 08/05/2015).
13. Grupo de trabajo Sector Zaragoza I Salud. Empleo de los inhibidores de la bomba de protones en la prevención de gastropatías secundarias a fármacos. Guía de Práctica Clínica. Enero 2012. Available at: http://www. guiasalud. es/GPC/GPC_509_IBP_gastropatias_2rias_fcos_completa. pdf.
14. Vallés R, Franzi A, Ferro JJ. Condiciones clínicas y terapéuticas que requieren gastroprotección. FMC 2014; 21: 528-33.
15. National Institute for Health and Clinical Excellence. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. July 2001. http://www. nice. org. uk/Guidance/TA27/Guidance/pdf/English (accessed 08/07/2015).
16. Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-38. DOI: 10.1038/ajg.2009.115
17. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-909. DOI: 10.1161/CIRCULATIONAHA.108.191087
18. Solís-García-del-Pozo J, Pérez-Pinar M, Fernández-Jiménez P, et al. Inappropriate use of proton pump inhibitors, guidelines and clinical research. Rev Esp Enferm Dig 2013; 105: 373. DOI: 10.4321/S1130-01082013000600016
19. Ahrens D, Chenot JF, Behrens G, et al. Appropriateness of treatment recommendations for PPI in hospital discharge letters. Eur J Clin Pharmacol 2010; 66: 1265-71. DOI: 10.1007/s00228-010-0871-9
20. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010; 5: 288-97. DOI: 10.2174/157488410793352067
21. Mat Saad AZ, Collins N, Lobo MM, et al. Proton pump inhibitors: A survey of prescribing in an Irish general hospital. Int J Clin Pract 2005; 59: 31-4. DOI: 10.1111/j.1742-1241.2004.00298. x
22. Niklasson A, Bajor A, Bergendal L. Overuse of acid suppressive therapy in hospitalised patients with pulmonary diseases. Respir Med 2003; 97: 1143-50. DOI: 10.1016/S0954-6111(03)00187-2
23. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44. DOI: 10.1001/jama.2009.261
24. Durand C, Willet K, Desilets A. Proton Pump Inhibitor use in hospitalized patients: Is overutilization becoming a problem? Clinical Medicine Insights: Clin Med Insights Gastroenterol 2012; 5: 65-76. DOI: 10.4137/CGast. S9588
25. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci 2001; 23: 116-7. DOI: 10.1023/A: 1011278030001
26. Martín-Echevarría E, Pereira A, Torralba M, et al. Evaluación del uso de los inhibidores de la bomba de protones en un servicio de medicina interna. Rev Esp Enferm Dig 2008; 100: 76-81. DOI: 10.4321/S1130-01082008000200003
27. Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007; 83: 66-8. DOI: 10.1136/pgmj.2006.051151
28. Haastrup P, Paulsen M, Begtrup L, et al. Strategies for discontinuation of proton pump inhibitors: A systematic review. Fam Pract 2014; 6: 625-30. DOI: 10.1093/fampra/cmu050